|Bid||277.50 x 1000|
|Ask||284.99 x 800|
|Day's Range||278.12 - 289.44|
|52 Week Range||268.62 - 380.76|
|Beta (3Y Monthly)||1.20|
|PE Ratio (TTM)||44.37|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Illumina, Inc. (ILMN) today announced preliminary revenue for the second quarter of fiscal year 2019, and updated its 2019 revenue guidance. Subject to quarter-end closing adjustments, the Company expects to report second quarter revenue of approximately $835 million, compared to $830 million in the second quarter of 2018. Approximately $30 million lower revenue than expected associated with population genomics initiatives, including a sizeable sequencing systems and consumables purchase that did not close as expected in the second half of June, which is now expected to close later in 2019.
Illumina, Inc. today announced that it has filed three additional patent infringement suits relating to BGI’s sequencing products, including the BGISeq-500, MGISeq-2000, and related chemistry reagents.
Illumina, Inc. announced today that the High Court of Justice, Chancery Division, Patents Court in the United Kingdom issued a judgment in its favor in the patent infringement suit filed against Ariosa Diagnostics, Inc.
Next-generation Sequencing-based Solution Provides Accurate, Fast and Scalable End-to-end Genome-wide Noninvasive Prenatal Testing
Illumina, Inc. today announced that its executives will be speaking at the following investor conference and invited investors to participate via webcast.
Illumina, Inc. today announced that it has filed another patent infringement suit against one of BGI Group’s subsidiaries, BGI Europe A/S. Illumina filed suit in the Maritime & Commercial High Court of Denmark.
LAS VEGAS, May 7, 2019 /PRNewswire/ -- The Healthy Nevada Project, a first-of-its-kind, community-based population health study combining genetic, clinical, environmental and social data, is expanding enrollment to Las Vegas. The Project aspires not only to offer genetic testing to every Nevadan interested in learning more about their health and genetic profile but ultimately, to develop and expand the Project for communities across the United States to drive positive health outcomes nationwide.
SAN CARLOS, Calif., April 25, 2019 /PRNewswire/ -- Helix today announced it is broadening its market focus to include health systems, payers and researchers who are interested in sequencing large population cohorts. Helix will be offering those partners its population health solutions, a suite of sequencing products and services built around the Helix proprietary Exome+™ assay, packaged with its workflow, CLIA/CAP lab, return of results platform and data capabilities. To lead this expansion, the company has named Marc Stapley as Chairman and CEO.
NEW YORK, NY / ACCESSWIRE / April 25, 2019 / Illumina, Inc. (NASDAQ: ILMN ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on April 25, 2019 at 5:00 PM Eastern ...
Illumina, Inc. (ILMN) today announced that it will issue results for first quarter 2019 following the close of market on Thursday, April 25, 2019. On the same day, at 2:00 pm Pacific Time (5:00 pm Eastern Time) Francis deSouza, President and Chief Executive Officer, and Sam Samad, Senior Vice President and Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results. Interested parties may access the live teleconference through the Investor Relations section of Illumina’s website under the “company” tab at www.illumina.com.
Illumina, Inc. today announced that it has filed a patent infringement suit against BGI Group’s subsidiary, Latvia MGI Tech SIA, in the Düsseldorf Regional Court in Germany.
Illumina (ILMN) and the Lundbeck Foundation GeoGenetics Centre at the University of Copenhagen, Denmark partner to explore the relationship between the evolutionary history of select mental and neurological disorders and infectious pathogens. One of the first projects of its kind worldwide, the endeavor aims to acquire new knowledge in terms of the medical and biological understanding of special factors underlying the development of human neuropsychiatric diseases through the ages. Ultimately, the project may provide a new approach to the development of medicines and other therapeutic treatments for mental and neurological conditions.
NEW YORK, Feb. 08, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Illumina, Inc. (ILMN) announced today that Sue Siegel has joined the company’s Board of Directors effective February 5, 2019. Ms. Siegel is Chief Innovation Officer at General Electric (GE) and CEO of GE Ventures. Ms. Siegel has more than 30 years of corporate, entrepreneurial and venture capital experience.
Illumina, Inc. (ILMN) today announced that it will issue results for fourth quarter and fiscal year 2018 following the close of market on Tuesday, January 29, 2019. On the same day, at 2:00 pm Pacific Time (5:00 pm Eastern Time) Francis deSouza, President and Chief Executive Officer, and Sam Samad, Senior Vice President and Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results. Interested parties may access the live teleconference through the Investor Relations section of Illumina’s website under the “company” tab at www.illumina.com.
NEW YORK, NY / ACCESSWIRE / January 7, 2019 / U.S. markets surged on Friday as employment data came in well above expectations. The Bureau of Labor Statistics reported 312,000 jobs were added in December, ...
Illumina, Inc. (ILMN) today announced that its executives will be speaking at the following investor conference and invited investors to participate via webcast. The live webcast can be accessed in the Investor Relations section of Illumina's web site under the "company" tab at www.illumina.com. A replay of the presentation will be posted on Illumina’s web site after the event and will be available for at least 30 days following.
NEW YORK, Dec. 10, 2018 -- Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of Pacific Biosciences of California, Inc. (NASDAQ:.
Illumina, Inc. (ILMN) today announced the launch of its new high-density genotyping array, the Infinium™ Global Diversity Array. This new array was developed for and inspired by the All of Us Research Program. The All of Us Research Program is a historic effort to gather data from one million or more people living in the United States, to accelerate human disease research and improve health. The All of Us Research Program is one of the country’s most ambitious biomedical research efforts ever undertaken.